Viking Therapeutics, Inc.
VKTX
$35.63
$0.160.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.81% | 22.31% | 51.67% | 42.50% | 33.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.63% | 105.15% | 70.71% | 50.68% | 49.68% |
| Operating Income | -160.63% | -105.15% | -70.71% | -50.68% | -49.68% |
| Income Before Tax | -227.05% | -139.43% | -77.32% | -36.83% | -28.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -227.05% | -139.43% | -77.32% | -36.83% | -28.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -227.05% | -139.43% | -77.32% | -36.83% | -28.02% |
| EBIT | -160.63% | -105.15% | -70.71% | -50.68% | -49.68% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -215.47% | -126.05% | -63.65% | -23.78% | -10.23% |
| Normalized Basic EPS | -215.18% | -125.77% | -63.72% | -23.86% | -10.33% |
| EPS Diluted | -215.47% | -126.05% | -63.65% | -23.78% | -10.23% |
| Normalized Diluted EPS | -215.18% | -125.77% | -63.72% | -23.86% | -10.33% |
| Average Basic Shares Outstanding | 3.31% | 5.45% | 7.93% | 10.55% | 15.63% |
| Average Diluted Shares Outstanding | 3.31% | 5.45% | 7.93% | 10.55% | 15.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |